NASDAQ:NSTG - NanoString Technologies Stock Price, News & Analysis

NanoString Technologies trades on the NASDAQ under the ticker symbol "NSTG."

NanoString Technologies Inc (NASDAQ:NSTG) issued its earnings results on Wednesday, July, 31st. The biotechnology company reported ($0.57) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.55) by $0.02. The biotechnology company earned $30.35 million during the quarter, compared to analyst estimates of $29 million. NanoString Technologies had a negative net margin of 68.16% and a negative return on equity of 118.03%. View NanoString Technologies' Earnings History.

NanoString Technologies is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for NanoString Technologies.

NanoString Technologies issued an update on its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided earnings per share guidance of $-2.4--2.2 for the period, compared to the Thomson Reuters consensus EPS estimate of $-2.24. The company issued revenue guidance of $118-123 million, compared to the consensus revenue estimate of $120.83 million.

4 analysts have issued twelve-month target prices for NanoString Technologies' shares. Their forecasts range from $18.00 to $35.00. On average, they anticipate NanoString Technologies' stock price to reach $23.50 in the next twelve months. This suggests that the stock has a possible downside of 14.8%. View Analyst Price Targets for NanoString Technologies.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NanoString Technologies in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NanoString Technologies.

Media stories about NSTG stock have trended negative this week, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. NanoString Technologies earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for NanoString Technologies.

Some companies that are related to NanoString Technologies include Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Audentes Therapeutics (BOLD), Regenxbio (RGNX), Sangamo Therapeutics (SGMO), Coherus Biosciences (CHRS), Editas Medicine (EDIT), Orchard Therapeutics (ORTX), Fate Therapeutics (FATE), Momenta Pharmaceuticals (MNTA) and Aerie Pharmaceuticals (AERI).

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoString Technologies investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Chipotle Mexican Grill (CMG), Precision Drilling (PD), AutoZone (AZO), Bank Of The Ozarks (OZRK), Designer Brands (DSW) and Eaton Vance Floating-Rate Income Trust (EFT).

NanoString Technologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (10.06%), Morgan Stanley (9.15%), BlackRock Inc. (8.73%), Nikko Asset Management Americas Inc. (7.10%), Vanguard Group Inc. (4.88%) and Cadian Capital Management LP (4.31%). Company insiders that own NanoString Technologies stock include David W Ghesquiere, K Thomas Bailey, Kirk Malloy, Lifesciences Ii LP Clarus, Mary Tedd Allen, Nicholas Galakatos, R Bradley Gray and William Young. View Institutional Ownership Trends for NanoString Technologies.

NSTG stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Bank of America Corp DE, Farallon Capital Management LLC, Cubist Systematic Strategies LLC, Platinum Investment Management Ltd., Bogle Investment Management L P DE, Sandler Capital Management and Lisanti Capital Growth LLC. Company insiders that have sold NanoString Technologies company stock in the last year include David W Ghesquiere, K Thomas Bailey, Kirk Malloy, Lifesciences Ii LP Clarus, Mary Tedd Allen, Nicholas Galakatos and R Bradley Gray. View Insider Buying and Selling for NanoString Technologies.

NSTG stock was acquired by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Cadian Capital Management LP, BlackRock Inc., Nuveen Asset Management LLC, Sumitomo Mitsui Trust Holdings Inc., Wells Fargo & Company MN, Vanguard Group Inc. and Citadel Advisors LLC. View Insider Buying and Selling for NanoString Technologies.

Shares of NSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NSTG stock can currently be purchased for approximately $27.57.

NanoString Technologies has a market capitalization of $977.08 million and generates $106.73 million in revenue each year. The biotechnology company earns $-77,400,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. NanoString Technologies employs 476 workers across the globe.View Additional Information About NanoString Technologies.

The official website for NanoString Technologies is http://www.nanostring.com/.

NanoString Technologies' mailing address is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. The biotechnology company can be reached via phone at 206-378-6266 or via email at [email protected]